INFLECTRA®
(Infliximab dyyb)
Documentation
Patented
Approved 2016
FDA Letter
FDA Label
Full Sequence
Brief Summary
Function Type: Antagonist
Target: TNFα
Indication Category: Autoimmunity
Patented
Approved 2016
FDA Letter
FDA Label
Full Sequence
Function Type: Antagonist
Target: TNFα
Indication Category: Autoimmunity